



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07C 401/00, A61K 31/59	A1	(11) International Publication Number: WO 90/10620 (43) International Publication Date: 20 September 1990 (20.09.90)
(21) International Application Number: PCT/US90/00954 (22) International Filing Date: 16 February 1990 (16.02.90) (30) Priority data: 321,030 9 March 1989 (09.03.89) US (71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, Madison, WI 53705 (US). (72) Inventors: DELUCA, Hector, F. ; 1809 Highway BB, Deerfield, WI 53531 (US). SCHNOES, Heinrich, K. ; 1806 Summit Avenue, Madison, WI 53705 (US). PERLMAN, Kato, L. ; 1 Chippewa Court, Madison, WI 53711 (US). SICINSKI, Rafal, R. ; University of Warsaw, Dept. of Chemistry, Pasteura 1, 02-093 Warsaw (PL). PRAHL, Jean, Martin ; 7 Georgetown Court, Madison, WI 53919 (US).		(74) Agents: WOZNY, Thomas, M.; Andrus, Sceales, Starke & Sawall, 735 N. Water Street, Suite 1102, Milwaukee, WI 53202 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC, NL (European patent), NO, RO, SE (European patent), SU. Published <i>With international search report.</i>
(54) Title: 19-NOR-VITAMIN D COMPOUNDS (57) Abstract This invention provides a novel class of vitamin D-related compounds, namely the 1 α -hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

19-Nor-Vitamin D Compounds

5 This invention was made with United States government support awarded by the Department of Health and Human Services (NIH), Grant number: DK-14881. The United States Government has certain rights in this invention.

10 This invention relates to biologically active vitamin D compounds. More specifically, the invention relates to 19-nor-analogs of 1α -hydroxylated vitamin D compounds and to a general process for their preparation.


Background

15 The 1α -hydroxylated metabolites of vitamin D -- most importantly $1\alpha,25$ -dihydroxyvitamin D_3 and $1\alpha,25$ -dihydroxyvitamin D_2 -- are known as highly potent regulators of calcium homeostasis in animals and humans, and more recently their activity in cellular
20 differentiation has also been established. As a consequence, many structural analogs of these metabolites, such as compounds with different side chain structures, different hydroxylation patterns, or different stereochemistry, have been prepared and
25 tested. Important examples of such analogs are 1α -hydroxyvitamin D_3 , 1α -hydroxyvitamin D_2 , various side chain fluorinated derivatives of $1\alpha,25$ -dihydroxyvitamin D_3 , and side chain homologated analogs. Several of
30 these known compounds exhibit highly potent activity in vivo or in vitro, and possess advantageous activity profiles and thus are in use, or have been proposed for use, in the treatment of a variety of diseases such as renal osteodystrophy, vitamin D-resistant rickets, osteoporosis, psoriasis, and certain malignancies.
35


-2-

Disclosure and Description of the Invention

A class of 1 α -hydroxylated vitamin D compounds not known heretofore are the 19-nor-analogs, i.e. compounds in which the ring A exocyclic methylene group (carbon 19) typical of all vitamin D system has been removed and replaced by two hydrogen atoms. Structurally these novel analogs are characterized by the general formula I shown below:




where x^1 and x^2 are each selected from the group consisting of hydrogen and acyl, and where the group R represents any of the typical side chains known for vitamin D type compounds. Thus, R may be an alkyl, hydrogen, hydroxyalkyl or fluoroalkyl group, or R may represent the following side chain:



wherein R^1 represents hydrogen, hydroxy or O-acyl, R^2 and R^3 are each selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group $--(CH_2)_m--$ where m is an integer having a value of from 2 to 5, R^4 is selected from the group consisting of hydrogen, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoroalkyl, R^5 is selected from the group consisting of hydrogen,

fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or, R^4 and R^5 taken together represent double-bonded oxygen, R^6 and R^7 are each selected from the group consisting of hydrogen, hydroxy, O-acyl, fluorine and alkyl, or, R^6 and R^7 taken together form a carbon-carbon double bond, and wherein n is an integer having a value of from 1 to 5, and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom.

Specific important examples of side chains are the structures represented by formulas (a), (b), (c), (d) and (e) below, i.e. the side chain as it occurs in 25-hydroxyvitamin D_3 (a); vitamin D_3 (b); 25-hydroxyvitamin D_2 (c); vitamin D_2 (d); and the C-24-epimer of 25-hydroxyvitamin D_2 (e).




In this specification and the claims, the term 'alkyl' signifies an alkyl radical of 1 to 5 carbons in all isomeric forms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, etc., and the terms 'hydroxyalkyl' and 'fluoroalkyl' refer to such an alkyl radical substituted by one or more hydroxy or fluoro groups respectively, and the term 'acyl' means an aliphatic acyl group of 1 to 5 carbons, such as formyl, acetyl, propionyl, etc. or an aromatic acyl group such as benzoyl, nitrobenzoyl or halobenzoyl. The term

-4-


'aryl' signifies a phenyl-, or an alkyl-, nitro- or halo-substituted phenyl group.

The preparation of 1α -hydroxy-19-nor-vitamin D compounds having the basic structure shown above can be accomplished by a common general method, using known vitamin D compounds as starting materials. Suitable starting materials are, for example, the vitamin D compounds of the general structure II:



where R is any of the side chains as defined above. These vitamin D starting materials are known compounds, or compounds that can be prepared by known methods.


20 Using the procedure of DeLuca et al. (U.S. Patent 4,195,027), the starting material is converted to the corresponding 1α -hydroxy-3,5-cyclovitamin D derivative, having the general structure III below, where X represents hydrogen and Q represents an alkyl, preferably methyl:



SUBSTITUTE SHEET

So as to preclude undesired reaction of the 1 α -hydroxy group in subsequent steps, the hydroxy group is converted to the corresponding acyl derivative, i.e. the compound III shown above, where X represents an acyl group, using standard acylation procedures, such as treatment with an acyl anhydride or acyl halide in pyridine at room temperature or slightly elevated temperature (30-70°C). It should be understood also that whereas the process of this invention is illustrated here with acyl protection of hydroxy functions, alternative standard hydroxy-protecting groups can also be used, such as, for example, alkylsilyl or alkoxyalkyl groups. Such protecting groups are well-known in the art (e.g. trimethylsilyl, triethylsilyl, t.-butyldimethylsilyl, or tetrahydrofuranyl, methoxymethyl), and their use is considered a routine modification of experimental detail within the scope of the process of this invention.

The derivative as obtained above is then reacted with osmium tetroxide, to produce the 10,19-dihydroxy analog, IV (where X is acyl), which is subjected to diol cleavage using sodium metaperiodate or similar vicinal diol cleavage reagents (e.g. lead tetraacetate) to obtain the 10-oxo-intermediate, having the structure V below (where X is acyl):




-6-

These two consecutive steps can be carried out according to the procedures given by Paaren *et al.* [J. Org. Chem. 48, 3819 (1983)]. If the side chain unit, R, carries vicinal diols (e.g. 24,25-dihydroxy- or 25,26-dihydroxy, etc.), these, of course, also need to be protected, e.g. via acylation, silylation, or as the isopropylidene derivative prior to the periodate cleavage reactions.

In most cases, the acylation of the 1 α -hydroxy group as mentioned above will simultaneously effect the acylation of side chain hydroxy functions, and these acylation conditions can, of course, be appropriately adjusted (e.g. elevated temperatures, longer reaction times) so as to assure complete protection of side chain vicinal diol groupings.

The next step of the process comprises the reduction of the 10-oxo-group to the corresponding 10-alcohol having the structure VI shown below (where X is acyl and Y represents hydroxy). When X is acyl, this reduction is carried out conveniently in an organic solvent at from about 0°C to about room temperature, using NaBH₄ or equivalent hydride reducing agents, selective for the reduction of carbonyl groups without cleaving ester functions. Obviously, when X is a hydroxy-protecting group that is stable to reducing agents, any of the other hydride reducing agents (e.g. LiAlH₄, or analogous reagents) may be employed also.




SUBSTITUTE SHEET

The 10-hydroxy intermediate is then treated with an alkyl- or arylsulfonylhalide (e.g. methanesulfonylchloride) in a suitable solvent (e.g. pyridine) to obtain the corresponding 10-O-alkyl- or arylsulfonyl derivative (the compound having the structure shown VI above, where Y is alkyl-SO₂O-, or aryl-SO₂O-, and this sulfonate intermediate is then directly reduced, with lithium aluminum hydride, or the analogous known lithium aluminum alkyl hydride reagents in an ether solvent, at a temperature ranging from 0°C to the boiling temperature of the solvent, thereby displacing the sulfonate group and obtaining the 10-deoxy derivative, represented by the structure VI above, where X and Y are both hydrogen. As shown by the above structure, a 1-O-acyl function in the precursor compound V is also cleaved in this reduction step to produce the free 1α-hydroxy function, and any O-acyl protecting group in the side chain would, of course, likewise be reduced to the corresponding free alcohol function, as is well understood in the art. If desired, the hydroxy groups at C-1 (or hydroxy groups in the side chain) can be reprotected by acylation or silylation or ether formation to the corresponding acyl, alkylsilyl or alkoxyalkyl derivative, but such protection is not required. Alternative hydroxy-protecting groups, such as alkylsilyl or alkoxyalkyl groups would be retained in this reduction step, but can be removed, as desired, at this or later stages in the process by standard methods known in the art.

The above 1α-hydroxy-10-deoxy cyclovitamin D intermediate is next solvolized in the presence of a low-molecular weight organic acid, using the conditions of DeLuca et al. (U.S. Patents 4,195,027 and 4,260,549). When the solvolysis is carried out in acetic acid, for example, there is obtained a

-8-

mixture of 1 α -hydroxy-19-nor-vitamin D 3-acetate and 1 α -hydroxy-19-nor-vitamin D 1-acetate (compounds VII and VIII, below), and the analogous 1- and 3-acylates are produced, when alternative acids are used for solvolysis.



15

Direct basic hydrolysis of this mixture under standard conditions then produces the desired 1 α -hydroxy-19-nor-vitamin D compounds of structure I above (where X¹ and X² are hydrogen). Alternatively, the above mixture of monoacetates may also be separated (e.g. by high pressure liquid chromatography) and the resulting 1-acetate and 3-acetate isomers may be subjected separately to hydrolysis to obtain the same final product from each, namely the 1 α -hydroxy-19-nor-vitamin D compounds of structure I. Also the separated monoacetates of structure VII or VIII or the free 1,3-dihydroxy compound can, of course, be reacylated according to standard procedures with any desired acyl group, so as to produce the product of structure I above, where X¹ and X² represent acyl groups which may be the same or different.

SUBSTITUTE SHEET

Biological Activity of 1 α -Hydroxy-19-Nor-Vitamin D Compounds

The novel compounds of this invention exhibit an unexpected pattern of biological activity, namely high potency in promoting the differentiation of malignant cells and little or no activity in calcifying bone tissue. This is illustrated by the biological assay results obtained for 1 α ,25-dihydroxy-19-nor-vitamin D₃ (compounds Ia), which are summarized in Tables 1 and 2, respectively. Table 1 shows a comparison of the activity of the known active metabolite 1 α ,25-dihydroxyvitamin D₃ and the 19-nor analog (Ia) in inducing the differentiation of human leukemia cells (HL-60 cells) in culture to normal cells (monocytes). Differentiation activity was assessed by three standard differentiation assays, abbreviated in Table 1 as NBT (nitroblue tetrazolium reduction), NSE (non-specific esterase activity), and PHAGO (phagocytosis activity). The assays were conducted according to known procedures, as given, for example, by DeLuca *et al.* (U.S. Patent 4,717,721) and Ostrem *et al.*, J. Biol. Chem. 262, 14164, 1987). For each assay, the differentiation activity of the test compounds is expressed in terms of the percent of HL-60 cells having differentiated to normal cells in response to a given concentration of test compound.

The results summarized in Table 1 clearly show that the new analog, 1 α ,25-dihydroxy-19-nor-vitamin D₃ (Ia) is as potent as 1 α ,25-dihydroxyvitamin D₃ in promoting the differentiation of leukemia cells. Thus in all three assays close to 90% of the cells are induced to differentiate by 1 α ,25-dihydroxy-vitamin D₃ at a concentration of 1×10^{-7} molar, and the same degree of differentiation (i.e. 90, 84 and 90%) is achieved by the 19-nor analog (Ia).

-10-

Table 1

Differentiation of HL-60 Cells

<u>1α,25-dihydroxyvitamin D₃</u> (moles/liter)		<u>% Differentiated Cells</u> (mean \pm SEM)		
		<u>NBT</u>	<u>NSE</u>	<u>PRAGO</u>
5	1 \times 10 ⁻⁷	86 \pm 2	89 \pm 1	87 \pm 3
	1 \times 10 ⁻⁸	60 \pm 2	60 \pm 3	64 \pm 2
	1 \times 10 ⁻⁹	33 \pm 2	31 \pm 2	34 \pm 1
10	1 α ,25-Dihydroxy-19-nor- vitamin D ₃ , (Ia) (moles/liter)			
	2 \times 10 ⁻⁷	94 \pm 2	95 \pm 3	94 \pm 2
	1 \times 10 ⁻⁷	90 \pm 4	84 \pm 4	90 \pm 4
	5 \times 10 ⁻⁸	72 \pm 3	73 \pm 3	74 \pm 3
15	1 \times 10 ⁻⁸	61 \pm 3	60 \pm 3	56 \pm 1
	1 \times 10 ⁻⁹	32 \pm 1	31 \pm 1	33 \pm 1

20 In contrast to the preceding results, the new 19-nor
 analog (Ia) exhibits no activity in an assay measuring the
 calcification of bone, a typical response elicited by vitamin D
 compounds. Relevant data, representing the results of an assay
 comparing the bone calcification activity in rats of
 25 1 α ,25-dihydroxyvitamin D₃ and 1 α ,25-dihydroxy-19-nor-vitamin D₃
 (Ia), are summarized in Table 2. This assay was conducted
 according to the procedure described by Tanaka et al.,
 Endocrinology 92, 417 (1973).

The results presented in Table 2 show the expected bone calcification activity of 1 α ,25-dihydroxyvitamin D₃ as reflected by the increase in percent bone ash, and in total ash at all dose levels. In contrast, the 19-nor analog 1a exhibits no activity at all three dose levels, when compared to the vitamin D-deficient (-D) control group.

Table 2			
<u>Calcification Activity</u>			
<u>Compound</u>	<u>Amount Administered*</u> (pmoles/day/7 days)	<u>% Ash</u> (mean \pm SEM)	<u>Total Ash (mg)</u> (mean \pm SEM)
-D (control)	0	19 \pm 0.8	23 \pm 1.2
1 α ,25-dihydroxy- vitamin D ₃	32.5	23 \pm 0.5	34 \pm 1.6
	65.0	26 \pm 0.7	36 \pm 1.1
	325.0	28 \pm 0.9	40 \pm 1.9
1 α ,25-dihydroxy-19- nor-vitamin D ₃ (1a)	32.5	22 \pm 0.9	28 \pm 1.6
	65.0	19 \pm 1.5	28 \pm 3.4
	325.0	19 \pm 1.2	30 \pm 2.4

* Each assay group comprised 6 rats, receiving the indicated amount of test compound by intraperitoneal injection daily for a period of seven days.

Thus the new 19-nor analog shows a selective activity profile combining high potency in inducing the

-12-

differentiation of malignant cells with very low or no bone calcification activity. The compounds of this novel structural class, therefore, can be useful as therapeutic agents for the treatment of malignancies. Because the differentiative activity of vitamin D compounds on keratinocytes of skin (Smith *et al.*, J. Invest. Dermatol. 86, 709, 1986; Smith *et al.*, J. Am. Acad. Dermatol. 19, 516, 1988) is believed to be an indication of successful treatment of psoriasis (Takamoto *et al.*, Calc. Tissue Int. 39, 360, 1986), these compounds should prove useful in treating this and other skin disorders characterized by proliferation of undifferentiated skin cells. These compounds should also find use in the suppression of parathyroid tissue, as for example, in cases of secondary hyperparathyroidism found in renal disease (Slatopolsky *et al.*, J. Clin. Invest. 74, 2136, 1984).

For treatment purposes, the novel compounds of this invention can be formulated as solutions in innocuous solvents, or as emulsions, suspensions or dispersions in suitable innocuous solvents or carriers, or as pills, tablets or capsules, containing solid carriers according to conventional methods known in the art. For topical applications the compounds are advantageously formulated as creams or ointments or similar vehicle suitable for topical applications. Any such formulations may also contain other pharmaceutically-acceptable and non-toxic excipients such as stabilizers, anti-oxidants, binders, coloring agents or emulsifying or taste-modifying agents.

The compounds are advantageously administered by injection, or by intravenous infusion of suitable sterile

SUBSTITUTE SHEET

solutions, or in the form of oral doses via the alimentary canal, or topically in the form of ointments, lotions, or in suitable transdermal patches. For the treatment of malignant diseases, the 19-nor-vitamin D compounds of this invention are administered to subjects in dosages sufficient to inhibit the proliferation of malignant cells and induce their differentiation into normal monocyte-macrophages. Similarly, for the treatment of psoriasis, the compounds may be administered orally or topically in amounts sufficient to arrest the proliferation of undifferentiated keratinocytes, and in the treatment of hyperparathyroidism, the compounds are administered in dosages sufficient to suppress parathyroid activity, so as to achieve parathyroid hormone levels in the normal range. Suitable dosage amounts are from 1 to 500 µg of compound per day, such dosages being adjusted, depending on diseases to be treated, its severity and the response or condition of the subject as well-understood in the art.

This invention is more specifically described by the following illustrative examples. In these examples specific products identified by Roman numerals and letters, i.e. Ia, Ib, ..., IIa, IIb, ..., etc. refer to the specific structures and side chain combinations identified in the preceding description.

Example 1

Preparation of 1α,25-dihydroxy-19-nor-vitamin D₃ (Ia)

(a) 1α,25-Dihydroxy-3,5-cyclovitamin D₃ 1-acetate, 6-methyl ether: Using 25-hydroxyvitamin D₃ (IIa) as starting material, the known 1α,25-dihydroxy-3,5-cyclovitamin D₃ derivative IIIa

-14-

(X=H) was prepared according to published procedures (DeLuca et al., U.S. Patent 4, 195,027 and Paaren et al., J. Org. Chem. 45, 3252 (1980)). This product was then acetylated under standard conditions to obtain the corresponding 1-acetate derivative IIIa (X=Ac).

(b) 10,19-Dihydro-1 α ,10,19,25-tetrahydroxy-3,5-cyclovitamin D₃ 1-acetate, 6-methyl ether (IVa): Intermediate IIIa (X=Ac) was treated with a slight molar excess of osmium tetroxide in pyridine according to the general procedure described by Paaren et al. (J. Org. Chem. 48, 3819 (1983)) to obtain the 10,19-dihydroxylated derivative IVa. Mass spectrum m/z (relative intensity), 506 (M⁺, 1), 488 (2), 474 (40), 425 (45), 396 (15), 285 (5), 229 (30), 133 (45), 59 (80), 43 (100). ¹H NMR (CDCl₃) δ 0.52 (3H, s, 18-CH₃), 0.58 (1H, m, 3-H), 0.93 (3H, d, J=6.1 Hz, 21-CH₃), 1.22 (6H, s, 26-CH₃ and 27-CH₃), 2.10 (3H, s, COCH₃), 3.25 (3H, s, 6-OCH₃), 3.63 (2H, m, 19-CH₂), 4.60 (1H, d, J=9.2 Hz, 5-H), 4.63 (1H, dd, 1 β -H), 4.78 (1H, d, J=9.2 Hz, 7-H).

(c) 1 α ,25-Dihydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D₃ 1-acetate, 6-methyl ether (Va): The 10,19-dihydroxylated intermediate IVa was treated with a solution of sodium metaperiodate according to the procedure given by Paaren et al. (J. Org. Chem. 48, 3819, 1983) to produce the 10-oxo-cyclovitamin D derivative (Va, X=Ac). Mass spectrum m/z (relative intensity) 442 (M⁺-MeOH) (18), 424 (8), 382 (15), 364 (35), 253 (55), 225 (25), 197 (53), 155 (85), 137 (100). ¹H NMR (CDCl₃) δ 0.58 (3H, s, 18-CH₃), 0.93 (3H, d, J=6.6 Hz, 21-CH₃), 1.22 (6H, s, 26-CH₃ and 27-CH₃), 2.15 (s, 3-OCOCH₃),

SUBSTITUTE SHEET

3.30 (3H, s, 6-OCH₃), 4.61 (1H, d, J=9.1 Hz, 6-H), 4.71 (1H, d, J=9.6 Hz, 7-H), 5.18 (1H, m, 1β-H).

It has been found also that this diol cleavage reaction does not require elevated temperatures, and it is, indeed, generally preferable to conduct the reaction at approximately room temperature.

(d) 1α-Acetoxy-10,25-dihydroxy-3,5-cyclo-19-nor-vitamin D₃ 6-methyl ether (VIa, X=Ac, Y=OH): The 10-oxo derivative Va (X=Ac) (2.2 mg, 4.6 μmol) was dissolved in 0.5 ml of ethanol and to this solution 50 μl (5.3 μmol) of a NaBH₄ solution (prepared from 20 mg of NaBH₄, 4.5 ml water and 0.5 ml of 0.01 N NaOH solution) was added and the mixture stirred at 0°C for ca. 1.5 h, and then kept at 0°C for 16 h. To the mixture ether was added and the organic phase washed with brine, dried over MgSO₄, filtered and evaporated. The crude product was purified by column chromatography on a 15 x 1 cm silica gel column and the alcohol VIa (X=Ac, Y=OH) was eluted with ethyl acetate hexane mixtures to give 1.4 mg (3 μmol) of product. Mass spectrum m/z (relative intensity) 476 (M⁺) (1), 444 (85), 426 (18), 384 (30), 366 (48), 351 (21), 255 (35), 237 (48), 199 (100), 139 (51), 59 (58).

(e) 1α,25-Dihydroxy-19-nor-vitamin D₃ (Ia, X¹=X²=H): The 10-alcohol (VIa, X=Ac, Y=OH) (1.4 mg) was dissolved in 100 μl anhydrous CH₂Cl₂ and 10 μl (14 μmol) triethylamine solution [prepared from 12 mg (16 μl) triethylamine in 100 μl anhydrous CH₂Cl₂], followed by 7 μl (5.6 μmol) mesyl chloride solution (9 mg mesyl chloride, 6.1 μl, in 100 μl anhydrous CH₂Cl₂) added at 0°C. The mixture was stirred at 0°C for 2 h. The solvents were removed with a stream of argon and the residue (comprising compound VIa, X=Ac, Y=CH₃SO₂O-) dissolved in 0.5 ml of

-16-

anhydrous tetrahydrofuran; 5 mg of LiAlH_4 was added at 0°C and the mixture kept at 0°C for 16 h. Excess LiAlH_4 was decomposed with wet ether, the ether phase was washed with water and dried over MgSO_4 , filtered and evaporated to give the 19-nor product VIa ($X=Y=H$).

This product was dissolved in 0.5 ml of acetic acid and stirred at 55°C for 20 min. The mixture was cooled, ice water added and extracted with ether. The other phase was washed with cold 10% sodium bicarbonate solution, brine, dried over MgSO_4 , filtered and evaporated to give the expected mixture of 3-acetoxy-1 α -hydroxy- and 1 α -acetoxy-3-hydroxy isomers, which were separated and purified by HPLC (Zorbax Sil column, 6.4 x 25 cm, 2-propanol in hexane) to give about 70 μg each of compounds VIIa and VIIIa. UV (in EtOH) λ_{max} 242.5 (OD 0.72), 251.5 (OD 0.86), 260 (OD 0.57).

Both 19-nor-1,25-dihydroxyvitamin D_3 acetates VIIa and VIIIa were hydrolyzed in the same manner. Each of the monoacetates was dissolved in 0.5 ml of ether and 0.5 ml 0.1 N KOH in methanol was added. The mixture was stirred under argon atmosphere for 2 h. More ether was added and the organic phase washed with brine, dried over anhydrous MgSO_4 , filtered and evaporated. The residue was dissolved in a 1:1 mixture of 2-propanol and hexane and passed through a Sep Pak column and washed with the same solvent. The solvents were evaporated and the residue purified by HPLC (Zorbax Sil, 6.4 x 25 cm, 10% 2-propanol in hexane). The hydrolysis products of VIIa and VIIIa were identical and gave 66 μg of Ia ($X^1=X^2=H$). Mass spectrum (m/z relative intensity) 404 (M^+) (100), 386 (41), 371 (20), 275 (53), 245 (51), 180 (43), 135 (72), 133 (72), 95 (82), 59 (18), exact mass calcd. for $\text{C}_{26}\text{H}_{44}\text{O}_3$ 404.3290, found

SUBSTITUTE SHEET

404.3272. ^1H NMR (CDCl_3) δ 0.52 (3H, s, 18- CH_3), 0.92 (3H, d, $J=6.9$ Hz, 21- CH_3), 1.21 (6H, s, 26- CH_3 and 27- CH_3), 4.02 (1H, m, 3a-H), 4.06 (1H, m, 10-H), 5.83 (1H, d, $J=11.6$ Hz, 7-H), 6.29 (1H, d, $J=10.7$ Hz, 6-H). UV (in EtOH), λ_{max} 243 (OD 0.725), 251.5 (OD 0.823), 261 (OD 0.598).

Example 2

Preparation of 1 α -hydroxy-19-nor-vitamin D_3 (Ib)

10 (a) With vitamin D_3 (IIb) as starting material, and utilizing the conditions of Example 1a, there is obtained known 1 α -hydroxy-3,5-cyclovitamin D_3 1-acetate, 6-methyl ether, compound IIIb ($\text{X}=\text{Ac}$).

15 (b) By subjecting intermediate IIIb ($\text{X}=\text{Ac}$), as obtained in Example 2a above to the conditions of Example 1b, there is obtained 10,19-dihydro-1 α ,10,19-trihydroxy-3,5-cyclovitamin D_3 1-acetate, 6-methyl ether IVb ($\text{X}=\text{Ac}$).

20 (c) By treatment of intermediate IVb ($\text{X}=\text{Ac}$) with sodium metaperiodate according to Example 1c above, there is obtained 1 α -hydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D_3 1-acetate, 6-methyl ether Vb ($\text{X}=\text{Ac}$).

25 (d) Upon reduction of the 10-oxo-intermediate Vb ($\text{X}=\text{Ac}$) under the conditions of Example 1d above, there is obtained 1 α -acetoxy-10-hydroxy-3,5-cyclo-19-nor-vitamin D_3 6-methyl ether VIb ($\text{X}=\text{Ac}$, $\text{Y}=\text{OH}$).

(e) Upon processing intermediate VIb ($\text{X}=\text{Ac}$, $\text{Y}=\text{OH}$) through the procedure given in Example 1e above, there is obtained 1 α -hydroxy-19-nor-vitamin D_3 (Ib, $\text{X}^1=\text{X}^2=\text{H}$).

-18-

Example 3

Preparation of 1 α ,25-dihydroxy-19-nor-vitamin D₂

- (a) Utilizing 25-hydroxyvitamin D₂ (IIc) as starting material and experimental conditions analogous to those of Example 1a, there is obtained 1 α ,25-dihydroxy-3,5-cyclovitamin D₂ 1-acetate, 6-methyl ether, compound IIIc (X=Ac).
- (b) Subjecting intermediate IIIc (X=Ac), as obtained in Example 3a above, to the reaction conditions of Example 1b, provides 10,19-dihydro-1 α ,10,19,25-tetrahydroxy-3,5-cyclovitamin D₂ 1-acetate, 6-methyl ether, IVc (X=Ac).
- (c) By treatment of intermediate IVc (X=Ac) with sodium metaperiodate according to general procedures of Example 1c above, there is obtained 1 α ,25-dihydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D₂ 1-acetate, 6-methyl ether Vc (X=Ac).
- (d) Upon reduction of the 10-oxo-intermediate Vc (X=Ac) under conditions analogous to those of Example 1d above, there is obtained 1 α -acetoxy-10,25-dihydroxy-3,5-cyclo-19-nor-vitamin D₂ 6-methyl ether VIc (X=Ac, Y=OH).
- (e) Upon processing intermediate VIc (X=Ac, Y=OH) through the procedural steps given in Example 1e above, there is obtained 1 α ,25-dihydroxy-19-nor-vitamin D₂ (Ic, X¹=X²=H).

Example 4

Preparation of 1 α -hydroxy-19-nor-vitamin D₂

- (a) With vitamin D₂ (IIc) as starting material, and utilizing the conditions of Example 1a, there is obtained known 1 α -hydroxy-3,5-cyclovitamin D₂ 1-acetate, 6-methyl ether, compound IIIc (X=Ac).
- (b) By subjecting intermediate IIIc (X=Ac), as obtained in Example 4a above to the conditions of Example 1b, there is

obtained 10,19-dihydro-1 α ,10,19-trihydroxy-3,5-cyclovitamin D₂ 1-acetate, 6-methyl ether, IVd (X=Ac).

5 (c) By treatment of intermediate IVb (X=Ac) with sodium metaperiodate according to Example 1c above, there is obtained 1 α -hydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D₂ 1-acetate, 6-methyl ether, Vd (X=Ac).


10 (d) Upon reduction of the 10-oxo-intermediate Vd (X=Ac) under the conditions of Example 1d above, there is obtained 1 α -acetoxy-10-hydroxy-3,5-cyclo-19-nor-vitamin D₂ 6-methyl ether, VId (X=Ac, Y=OH).

(e) Upon processing intermediate VId (X=Ac, Y=OH) through the procedure given in Example 1e above, there is obtained 1 α -hydroxy-19-nor-vitamin D₂ (Id, X¹=X²=H).


-20-

CLAIMS

1. Compounds having the formula



where X^1 and X^2 are each selected from the group consisting of hydrogen, acyl, alkylsilyl and
 15 alkoxyalkyl, and where R is selected from the group consisting of alkyl, hydrogen, hydroxyalkyl, fluoroalkyl and a side chain of the formula




wherein R^1 represents hydrogen, hydroxy or O-acyl, R^2 and R^3 are each selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, or, when taken
 30 together represent the group $-(CH_2)_m-$ where m is an integer having a value of from 2 to 5, R^4 is selected from the group consisting of hydrogen, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoroalkyl, R^5 is selected from the group consisting of hydrogen,

fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or, R^4 and R^5 taken together represent double-bonded oxygen, R^6 and R^7 are each selected from the group consisting of hydrogen, hydroxy, O-acyl, fluorine and alkyl, or, R^6 and R^7 taken together form a carbon-carbon double bond, and wherein n is an integer having a value of from 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom.

2. The compounds according to Claim 1 where X^1 and X^2 represent hydrogen, and where R^1 is hydroxy, both of R^2 and R^3 are selected from the group consisting of methyl, trifluoromethyl, ethyl and propyl, both of R^6 and R^7 are hydrogen, or together form a carbon-carbon double bond, R^4 and R^5 are hydrogen and n is an integer having the values 1, 2 or 3.


3. $1\alpha,25$ -dihydroxy-19-nor-vitamin D_3 .
4. 1α -hydroxy-19-nor-vitamin D_3 .
5. $1\alpha,25$ -dihydroxy-19-nor-vitamin D_2 .
6. 1α -hydroxy-19-nor-vitamin D_2 .
7. 1α -hydroxy-19-nor-24 epi-vitamin D_2 .
8. $1\alpha,25$ -dihydroxy-19-nor-24 epi-vitamin D_2 .
9. Compounds having the formula



-22-


where R represents a side chain as defined in Claim 1, Q represents an alkyl and X is selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl.

10. Compounds having the formula:



where R is a side chain as defined in Claim 1, Q represents an alkyl and X is selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl.

11. Compounds of the structure:



SUBSTITUTE SHEET

-23-

where R is a side chain as defined in Claim 1, Q represents an alkyl, X is selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl, and Y is selected from the group consisting of hydroxy, hydrogen and protected hydroxy where the protecting group is acyl, alkylsilyl or alkoxyalkyl.

12. A method for inducing cell differentiation in malignant cells which comprises exposing said cells to an amount of at least one of the compounds of Claim 1 sufficient to induce differentiation.

13. The method of Claim 12 wherein the cells are leukemia cells.

14. The method of Claim 12 where the compound in a pharmaceutically acceptable vehicle is administered orally.

15. The method of Claim 12 where the compound is administered parenterally.

16. The method of claim 12 where the compound is administered topically.

17. A method for treating proliferative skin disorders in mammals which comprises administering to said mammals an amount of at least one of the compounds of Claim 1 effective to alleviate said disorder.

18. The method of Claim 17 where the disorder is psoriasis.

19. The method of Claim 17 where the compound is administered orally.

20. The method of Claim 17 where the compound is administered parenterally.

21. The method of Claim 17 where the compound in a pharmaceutically acceptable vehicle is administered topically.

SUBSTITUTE SHEET

-24-

22. A method for treating disorders of primary and secondary hyperparathyroidism which comprises suppressing parathyroid activity by administering to patients having such disorders an amount of at least one of the compounds of Claim 1 sufficient to suppress parathyroid activity.

23. A pharmaceutical composition comprising at least one of the compounds of Claim 1 together with a pharmaceutically acceptable excipient.

24. A pharmaceutical composition according to Claim 23 wherein the compound is in a solid or liquid vehicle ingestible by and non-toxic to mammals.

25. A pharmaceutical composition in accordance with Claim 23 where the compound is $1\alpha,25$ -dihydroxy-19-nor-vitamin D_3 .

26. A pharmaceutical composition in accordance with Claim 23 where the compound is 1α -hydroxy-19-nor-vitamin D_3 .

27. A pharmaceutical composition in accordance with Claim 23 where the compound is $1\alpha,25$ -dihydroxy-19-nor-vitamin D_2 .

28. A pharmaceutical composition in accordance with Claim 23 where the compound is 1α -hydroxy-19-nor-vitamin D_2 .

29. A method for treating neoplastic diseases which comprises administering to a patient having a neoplastic disease at least one of the compounds of Claim 1 in an amount sufficient to induce the differentiation of the malignant cells characteristic of the neoplastic disease to non-malignant macrophages.

30. The method of Claim 29 where the compound is $1\alpha,25$ -dihydroxy-19-nor-vitamin D_3 .

31. The method of Claim 29 where the compound is administered orally as a single dosage form

SUBSTITUTE SHEET

in a solid or liquid vehicle ingestible by and non-toxic to the patient.

32. The method of Claim 31 where the dosage form contains from about 0.5 μg to about 50 μg .

33. The method of Claim 29 where the compound is administered in an amount from about 1 μg to about 500 μg per day.

34. The method of claim 29 where the compound is administered topically.

35. The method of claim 29 where the compound is administered parenterally.

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US 90/00954**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC⁵: C 07 C 401/00, A 61 K 31/59																	
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 20%; border: none;">Classification System ¹</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;"> IPC⁵ </td> <td style="border: none; vertical-align: top;"> C 07 C 401/00, A 61 K 31/00 </td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 10px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System ¹	Classification Symbols	IPC⁵	C 07 C 401/00, A 61 K 31/00											
Classification System ¹	Classification Symbols																
IPC⁵	C 07 C 401/00, A 61 K 31/00																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border: none;"> <tr> <th style="width: 10%; border: none; font-size: x-small;">Category ¹⁰</th> <th style="width: 60%; border: none; font-size: x-small;">Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border: none; font-size: x-small;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: none; vertical-align: top; text-align: center;">A</td> <td style="border: none; vertical-align: top;"> Journal of the Chemical Society, Perkin Transactions I, 1978(6), London, GB, B. Lythgoe et al.: "Calciferol and its relatives. Part 22. A direct total synthesis of vitamin D₂ and Vitamin D₃", pages 590-595 see page 591, compound 7 -- </td> <td style="border: none; vertical-align: top; text-align: center;">1</td> </tr> <tr> <td style="border: none; vertical-align: top; text-align: center;">A</td> <td style="border: none; vertical-align: top;"> EP, A, 0250755 (SUMITOMO PHARMACEUTICALS LTD) 7 January 1988 see the whole document -- </td> <td style="border: none; vertical-align: top; text-align: center;">1, 23</td> </tr> <tr> <td style="border: none; vertical-align: top; text-align: center;">A</td> <td style="border: none; vertical-align: top;"> WO, A, 85/03300 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 1 August 1985 see the whole document -- </td> <td style="border: none; vertical-align: top; text-align: center;">1, 9-11, 23</td> </tr> <tr> <td style="border: none; vertical-align: top; text-align: center;">A</td> <td style="border: none; vertical-align: top;"> US, A, 4448726 (DE LUCA et al.) 15 May 1984 see the whole document ----- </td> <td style="border: none; vertical-align: top; text-align: center;">9</td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	Journal of the Chemical Society, Perkin Transactions I, 1978(6), London, GB, B. Lythgoe et al.: "Calciferol and its relatives. Part 22. A direct total synthesis of vitamin D ₂ and Vitamin D ₃ ", pages 590-595 see page 591, compound 7 --	1	A	EP, A, 0250755 (SUMITOMO PHARMACEUTICALS LTD) 7 January 1988 see the whole document --	1, 23	A	WO, A, 85/03300 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 1 August 1985 see the whole document --	1, 9-11, 23	A	US, A, 4448726 (DE LUCA et al.) 15 May 1984 see the whole document -----	9
Category ¹⁰	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
A	Journal of the Chemical Society, Perkin Transactions I, 1978(6), London, GB, B. Lythgoe et al.: "Calciferol and its relatives. Part 22. A direct total synthesis of vitamin D ₂ and Vitamin D ₃ ", pages 590-595 see page 591, compound 7 --	1															
A	EP, A, 0250755 (SUMITOMO PHARMACEUTICALS LTD) 7 January 1988 see the whole document --	1, 23															
A	WO, A, 85/03300 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 1 August 1985 see the whole document --	1, 9-11, 23															
A	US, A, 4448726 (DE LUCA et al.) 15 May 1984 see the whole document -----	9															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION																	
Date of the Actual Completion of the International Search <div style="text-align: center; font-size: large;">4th May 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-size: large;">- 5. 06. 90</div>																
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> MISS T. TAZELAAR </div>																

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 1....., because they relate to subject matter not required to be searched by this Authority, namely:

1). Claims 12-22, 29-35.

See PCT rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9000954
SA 35033

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 30/05/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0250755	07-01-88	JP-A- 63045249	26-02-88
WO-A- 8503300	01-08-85	AU-B- 587174	10-08-89
		AU-A- 3837285	09-08-85
		BE-A- 901601	17-05-85
		CH-A- 665835	15-06-88
		DE-T- 3590021	23-01-86
		FR-A, B 2558828	02-08-85
		GB-A, B 2153358	21-08-85
		JP-T- 61501147	12-06-86
		NL-T- 8520009	02-12-85
		US-A- 4689180	25-08-87
US-A- 4448726	15-05-84	DE-A- 3472954	01-09-88
		EP-A, B 0125909	21-11-84
		JP-A- 59212466	01-12-84

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.